European glucose monitoring market set to double by 2016
This article was originally published in Clinica
Executive Summary
Europe’s continuous glucose monitoring (CGM) market will more than double by 2016, analysts Frost & Sullivan believe. This growth is in response primarily to the increasing demand for an easy-to-use and patient-friendly glucose-monitoring device. The segment will generate revenues totalling $52m in 2016, up from an estimated $23.5m in 2009, according to the report European Market for Continuous Glucose Monitoring, which covers the Benelux countries, France, Germany, Italy, Scandinavia, Spain and the United Kingdom.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.